Global Klinefelter
Syndrome Treatment Market Overview
Klinefelter syndrome refers to a rare form
of the genetic condition where the male child is born with an additional X
chromosome. Klinefelter syndrome generally affects males and can adversely
affect testicular growth and can result in smaller testicles. Klinefelter
syndrome leads to lower production of testosterone. Klinefelter syndrome may
lead to a reduction in the muscle mass, reduced facial and body hair, and
enlarged breast tissue. The syndrome has different symptoms on different
people, and it is a very rare condition. As per the National Human Genome
Research Institute, Klinefelter syndrome is found in 1 out of every 500 to 1000
newborn male infants.
The Klinefelter syndrome treatment market
research
report is projected to reach USD 1.54 Billion by 2030 at 3.96% CAGR during the
forecast period 2022-2030. Owing to these unidentifiable symptoms, the syndrome
is hard to diagnose, as per the researchers of national human research
institutes. This factor creates a high need for proper diagnosis and treatment
methods, leading exponential growth to the global Klinefelter syndrome
treatment market. Further, awareness activities undertaken by NIH and FDA
towards this syndrome has propelled the market growth for the treatment of
Klinefelter syndrome.
Market
Segmentation
The global Klinefelter syndrome treatment
market is studied for different treatment methods and the end-users of such
treatments. Breast tissue removal, fertility treatment, and testosterone
replacement therapy are some of the treatments undertaken to tackle the
Klinefelter syndrome. Different treatments given under fertility treatment
include hormone treatments and surgeries. End-users of such Klinefelter
syndrome treatment options are ambulatory surgeries, hospitals and clinics,
academic institutes, and medical research institutes.
Detailed Regional
Analysis
The global Klinefelter syndrome treatment market
report
includes an in-depth analysis of regional segments. The regional segments
studied include North America, Europe, Asia Pacific, the Middle East &
Africa, and Latin America. North America
is projected to dictate the global Klinefelter syndrome treatment market. This
can be attributed to the market players investing in the development of new
drug product innovations. Further, a high presence of treatment centers in the
region for this syndrome, along with the rising awareness towards this, among
people has contributed to the booming ascension of the Klinefelter syndrome
treatment market in the region.
Europe is expected to trail behind North
America and garner the second-largest share in the global Klinefelter syndrome
treatment market. This can be attributed to the mounting prevalence of
geriatric population in Europe. Mounting prevalence of the Klinefelter syndrome
is another factor causative of the growth in the Klinefelter syndrome treatment
market of Europe. Rising research activities for this syndrome in Europe has
proliferated growth rates in the regional market during the assessment period.
According to the report by Europe PMC, the prevalence of Klinefelter syndrome
in males, in 2017, with breast cancer was found to be around 7.5% which was
much higher than the previously recorded 3% rate. This connection is promoting
a higher degree of research and development to discover new treatment methods
for Klinefelter syndrome.
Asia Pacific’s Klinefelter syndrome
treatment market is expected to ascend at the fastest rate during the forecast
period. This a be attributed to the changing lifestyles of people residing in
the region. Further proliferation observed in the population of the region is
another factor responsible for the fast-paced growth of the Klinefelter
syndrome treatment market over the assessment period. Mounting awareness among
the general public regarding this disorder and burgeoning healthcare
expenditure in the region are some of the other factors contributing to the
upscaling noted in the APAC’s Klinefelter syndrome treatment market.
Key Players
Some of the notable vendors functioning in
the Klinefelter syndrome treatment market include Allergan plc, AbbVie, Inc.,
Endo Pharmaceuticals, Inc., Kyowa Kirin International plc, Eli Lilly and
Company, Mylan N.V., Lupin Pharmaceuticals, and Pfizer, Inc.
Industry Update
July 2019: The world’s first clinic that
treats Klinefelter syndrome has opened at Guy’s Hospital, near London Bridge.
This clinic has brought together all medical facilities required for a
patient’s treatment.
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting
Services. MRFR team have supreme objective to provide the optimum quality
market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research
and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
0 Comments